Illumina, Inc. (ILMN)
|52 Week Range||173.45-248.87|
|1y Target Est||-|
|DCF Unlevered||ILMN DCF ->|
|DCF Levered||ILMN LDCF ->|
|Debt / Equity||76.47%||Buy|
Upgrades & Downgrades
Latest ILMN news
LGND or ILMN: Which Is the Better Value Stock Right Now?
6 June 2023
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Ligand Pharmaceuticals (LGND) and Illumina (ILMN). But which of these two companies is the best opti...
3 Stocks, 1 Potentially Explosive Growth Theme | June 5, 2023
5 June 2023
#Morningstar #StockMarket #Investing Plus our take on Nvidia stock and our market outlook for June. Read more from David Sekera here: https://www.morningstar.com/stocks/2-undervalued-medtech-stocks-op...
Illumina's (ILMN) New AI Tool to Predict Genomics Disease
2 June 2023
Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.
The Market Continues To Underprice Illumina's Stock And Its Genomics Leadership
1 June 2023
Illumina is undervalued by 23% according to a discounted cash flow analysis, with a fair value of $253.94. The company aims to expand into the $120bn TAM industries of oncology testing, genetic diseas...
Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23
31 May 2023
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.
Carl Icahn Buys Activist Target Illumina, Adds to Southwest Gas Stake
30 May 2023
Billionaire investor Carl Icahn (Trades, Portfolio) disclosed his firm's first-quarter equity portfolio earlier this month.
Illumina shareholders vote to elect one of Carl Icahn's candidates to its board after proxy fight
25 May 2023
Illumina Inc. ILMN, -12.05% shareholders voted Thursday to elect one of activist investor Carl Icahn's nominees to its board, and voted against the re-election of company Chairman John Thompson, accor...
Illumina shareholders vote to install Carl Icahn board nominee, oust chair
25 May 2023
Carl Icahn has accused Illumina's management and board of poor oversight, particularly with regard to the company's acquisition of cancer test maker Grail.
Is Illumina Stock A Better Pick Over TMO?
25 May 2023
ILMN trades at a higher valuation of 7.3x trailing revenues, compared to 4.6x for TMO, partly due to its financial position.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >